As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: April 11, 2013
by Vonda J. Sines for Yahoo News:
California researchers have solved one important mystery regarding how Alzheimer’s disease operates. Their discovery of a link between the illness and an overactive enzyme could eventually lead to a way to prevent the disease.
Scientists at The Scripps Research Institute (TSRI) in California have established a connection between Alzheimer’s and the over-activation of an enzyme dubbed AMPK, according to ScienceDaily. The team, led by Professor Franck Polleux, published its findings in the journal Neuron.
After the California researchers blocked AMPK in mouse models, neurons did not show the loss of synapses typically found in the early phase of Alzheimer’s. Their discovery highlights the potential of developing new therapies to target factors that cause AMPK overactivation in human brains.
The Alzheimer’s Association reports that an estimated 5.2 million Americans have Alzheimer’s disease. Every 68 seconds, another American develops this devastating form of dementia. By 2050, experts expect the frequency to drop to every 33 seconds.
Experts believe both genetics and environmental factors play a role in developing the illness. However, they don’t know the exact cause, according to PubMed Health.
Researchers have long known that small collections of amyloid beta, a protein, can cause early-stage patients to start to lose synapses, which are neuron-to-neuron points of connection. What they haven’t been able to figure out is specifically how the process unfolds.
After multiple research groups found hints that AMPK might be important to Alzheimer’s, Polleux decided to investigate whether an interaction involving amyloid beta and a modification of a protein known as tau with AMPK could cause brain damage in Alzheimer’s patients. One of the California scientists discovered that a calcium influx into neurons jump-starts an enzyme known as CAMKK2, believed to be the main AMPK instigator in neurons.
Further studies using genetically engineered mice that produce too much mutant amyloid beta resulted in a condition resembling Alzheimer’s. After various experiments involving CAMKK2 and AMPK, the eventual California findings suggested that amyloid beta is a contributor to developing Alzheimer’s, by way of AMPK and primarily by enabling tau toxicity.
The researchers are currently conducting more experiments to find any other toxic process that’s related to AMPK overactivation and that might have a role in the progression of Alzheimer’s.
My late father-in-law developed signs of Alzheimer’s at around the same age my husband is now. My husband has short-term memory issues supposedly related to another health condition. However, every time he mixes up the syntax of a sentence or can’t think of the name of a person or of a familiar object, we each wonder the same thing: Could it be Alzheimer’s? Our hope is that the link between Alzheimer’s and an overactive enzyme will lead to even earlier diagnoses, if not a means of prevention.
Thirty-six million people worldwide suffer from Alzheimer’s disease and dementia. In Canada, 25,000 new cases are diagnosed each year. Those sobering numbers have researchers around the globe racing to come up with new ways to...
he Food and Drug Administration issued new guides on drug development for neurological disorders. This sets the stage for possible treatments for Alzheimer’s. The disease-oriented development guide documents will provide details on how researchers...
For young adults with autosomal dominant Alzheimer’s disease (AD), molecular markers can identify changes associated with the disease before clinical onset, according to a study published online Feb. 12 in JAMA Neurology. Yakeel T. Quiroz, Ph.D., from Massachusetts...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.